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There are limited real-world data on prevalence and predictors of dual antiplatelet therapy
(DAPT) prolongation beyond one year after acute coronary syndrome (ACS). We have
explored such issue in the START ANTIPLATELET Registry, which is a prospective, obser-
vational, multicenter, Italian registry performed in seven Italian cardiology institutions includ-
ing patients admitted for ACS and followed up to one year. Out of a total population of 840
ACS patients, 596 patients had completed 12-month follow-up being on DAPT. Decision to
prolong DAPT beyond one year was taken in 79 patients (13%), whereas in 517 patients
DAPT was stopped. The strongest predictors of DAPT continuation were a new cardiovas-
cular events after the index admission event (OR 3.3, 95% CI 1.4–7.7), no bleeding compli-
cations (OR 3.2, 95% CI 1.2–8.3) and no anemia during one-year follow-up (OR 2.6, 95% CI
1.1–5.9); other independent predictors were renal failure (OR 2.5, 95% CI 1.3–5.0) and
peripheral artery disease (OR 1.8, 95% CI 1.1–3.0). The choice of DAPT prolongation was
not correlated with younger ager, presence of diabetes mellitus, coronary angioplasty as ini-
tial treatment strategy or type of implanted stent (drug-eluting vs bare metal). In conclusion,
this study provides a real-world snapshot on the factors influencing the option to continue
DAPT beyond one year after ACS; a low bleeding risk seems to influence the choice to pro-
long DAPT more than a high ischemic risk.
Introduction
Current guidelines on myocardial infarction (MI) and non-ST-segment elevation acute coro-
nary syndromes (NSTE-ACS) recommend as routine strategy the use of dual antiplatelet
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therapy (DAPT, aspirin plus a P2Y12 inhibitor) up to one year after the index event and then to
continue with a single-drug approach, usually aspirin.[1–3] However, large-sized registries have
shown that at least 20% of patients who are event-free at one year post-MI and receive a single
antiplatelet treatment will suffer a new cardiovascular event within five years.[4,5] On the other
hand, sub-analyses from controlled randomized trials had suggested that DAPT prolongation
beyond one year after ACS is associated with reduction of ischemic cardiovascular complica-
tions;[6,7] more recently, the randomized PEGASUS and DAPT trials have demonstrated a
decrease of major adverse cardiovascular events (MACE) with prolonged DAPT after MI or cor-
onary stenting, respectively, compared to aspirin alone, at the price of a significant increase of
non-fatal bleeding.[8,9] Thus, at one year after ACS it appears crucial to carefully consider and
balance on an individual basis the ischemic and bleeding risks and tailor a long-term antithrom-
botic strategy approach accordingly. Of note, the 2015 Guidelines of the European Society of Car-
diology on NSTE-ACS indicate the possibility to use in selected patients a P2Y12 inhibitor in
addition to aspirin beyond one year with class of recommendation IIb and level of evidence B.[1]
To date, there are limited real-world data on the proportion of patients for whom the pro-
longation of DAPT beyond one year after ACS is deemed favorable in terms of net clinical
benefit; moreover, no previous study has specifically evaluated independent predictors of
DAPT prolongation in this setting. Thus, we have explored this issue in the multicenter, Italian
START ANTIPLATELET Registry.
Materials and methods
START ANTIPLATELET is a prospective, real-world registry performed in seven Italian cardi-
ology institutions on patients admitted for ACS. In this paper we present data on the first 840
patients who have completed 1-year follow-up by January 31, 2017. Inclusion criteria were: age
18 years; written informed consent for study participation; admission for ACS (either STEMI
or NSTE-ACS). To reduce selection bias, no explicit exclusion criteria were present; moreover,
two specific and fixed working days in the week (for example Tuesday and Friday) were chosen
at each site and all consecutive patients with ACS admitted in those days were enrolled.
The study design consisted of a clinical evaluation at the time of hospital stay (baseline
visit), at six-month and 1-year follow-up. Demographic data, clinical characteristics, risk fac-
tors and treatment modalities were collected at baseline; the occurrence of adverse events,
both cardiovascular events and bleeding complications, was recorded at the 1-year evaluation,
as well as the type of therapy given during follow-up, drug-related side effects, duration and
compliance to antithrombotic treatments. Only documented adverse events were considered
relevant, as defined in current guidelines and with the date of any event being after the baseline
visit. Individual data were entered into an electronic case report form including various plausi-
bility checks for the considered variables.
START-ANTIPLATELET is a branch of the START registry (Survey on anTicoagulated
pAtients RegisTer, NCT02219984),[10] promoted by the Arianna Anticoagulazione Founda-
tion, Bologna. The registry was investigators-driven, non-sponsored and was approved by the
Ethic Committee of each participating institution (Campus Bio-Medico University of Rome;
Monaldi Hospital and "Luigi Vanvitelli" University of Campania; "Federico II" University of
Naples; University of Perugia; University Hospital of Padua; La Sapienza University of Rome;
University of Florence).
Definitions and endpoints
For the purpose of this analysis, we have included only patients receiving DAPT throughout
the 1-year follow-up and we have considered separately those patients according to the
Predictors of DAPT prolongation after ACS
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decision of the treating cardiologist to continue or not DAPT beyond one year. Aim was to
describe independent predictors of DAPT prolongation beyond one year after ACS in a real-
world setting. The study was performed before ticagrelor being licensed in Italy for clinical use
beyond one year in patients with MI; therefore, DAPT continuation was performed with clopi-
dogrel 75 mg/day in all patients. MACE were defined as cardiovascular death, myocardial
infarction or stroke. Major bleeding was defined according to the Thrombolysis in Myocardial
Infarction (TIMI) classification, as intracranial bleeding or clinically overt bleeding associated
with a decrease in hemoglobin of more than 5 g/dL.
Statistics
Categorical variables are expressed as number (percentage). Continuous variables are indi-
cated as median (interquartile range), unless otherwise specified. Continuous variables were
compared by t-test for normally distributed values (as assessed by Kolmogorov-Smirnov test),
otherwise the Mann-Whitney U-test was applied. We investigated clinical characteristics being
independent predictors of DAPT continuation beyond one year by logistic regression: each of
the variables indicated in Table 1 was first evaluated in a univariate model, and only those vari-
ables with P value<0.15 were then entered into the final model of multivariable logistic regres-
sion analysis. Odds ratios (OR), 95% confidence interval (CI) and corresponding P values are
presented. All calculations were performed by the SPSS 12.0 software and P values<0.05 (two-
tailed) were considered significant.
Results
Out of a total population of 840 ACS patients with complete follow-up, 596 patients had con-
tinued DAPT up to 12 months; at 1-year evaluation, in 79 (13%) patients the treating cardiolo-
gist decided to prolong DAPT, whereas in 517 patients (87%) DAPT was stopped.
Table 1 shows demographic and clinical characteristics of patients continuing or not con-
tinuing DAPT beyond one year. Patients who prolonged DAPT had a significantly higher
prevalence of previous percutaneous coronary intervention (PCI) and MI prior to the index
event compared to those who did not (34% vs 17% and 30% vs 19%, respectively), as well as
more elevated use of clopidogrel, instead of the newer P2Y12 inhibitors, at baseline (49% vs
28%). The prevalence of elderly patients (age >75 years), BMI at the extremes (potentially
influencing the perceived bleeding risk during antiplatelet therapy), diabetes mellitus, prior
transient ischemic attack (TIA)/stroke, use of PCI with stenting (vs medical therapy or bypass
surgery) and penetration of drug-eluting stents (DES) were similar in the two groups, whereas
there was a trend towards higher NSTE-ACS presentation, peripheral artery disease and renal
failure in patients with DAPT continuation (S1 File).
At multivariable analysis, independent predictors of DAPT prolongation beyond one year
were recurrent ischemic events (OR 3.3, 95% CI 1.4–7.7), moderate to severe renal failure (OR
2.5, 95% CI 1.3–5.0), peripheral artery disease (OR 1.8, 95% CI 1.1–3.0), no anemia (OR 2.6,
95% CI 1.1–5.9) and no bleeding event during 1-year follow-up (OR 3.2, 95% CI 1.2–8.3) (Fig
1). No relationship between younger ager, presence of diabetes mellitus, PCI as treatment
strategy for the ACS, DES implantation and DAPT prolongation was observed (S1 File).
We have also assessed the ischemic and bleeding risk profile of patients continuing and not
continuing DAPT by two contemporary scores, i.e. the atherothrombotic risk score derived
from the TRA 2˚P population [11] and the PRECISE-DAPT score for the bleeding risk;[12]
interestingly, values of both scores were similar in patients with and without DAPT prolonga-
tion (Fig 2).
Predictors of DAPT prolongation after ACS
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Age (years) 68 (59;77) 70 (61;80) 0.53
Age >75 years 161 (31) 30 (38) 0.28
Female gender 117 (23) 19 (24) 0.89
Clinical presentation 0.09
STEMI 272 (53) 33 (42)
NSTE-ACS 245 (47) 46 (58)
Current cigarette smoking 261 (51) 37 (47) 0.63
Systemic hypertension 372 (72) 55 (70) 0.77
Diabetes mellitus 141 (27) 18 (23) 0.48
Dyslipidaemia 259 (50) 42 (53) 0.70
Previous MI 100 (19) 24 (30) 0.036
Previous PCI 87 (17) 27 (34) 0.001
Previous major bleeding 13 (3) 2 (3) 0.71
Previous TIA/stroke 29 (6) 3 (4) 0.69
Peripheral artery disease 106 (21) 24 (30) 0.07
Concomitant atrial fibrillation 39 (8) 4 (5) 0.58
LVEF40% 107 (21) 19 (24) 0.60
BMI <18 kg/m2 2 (0.4) 0 0.62
BMI 30 kg/m2 100 (19) 13 (17) 0.65
Anemia* 88 (17) 8 (10) 0.17
Platelets <100.000/mm3 6 (1) 3 (4) 0.20
Creatinine clearance <50 mL/min 62 812) 16 (20) 0.07
Therapy for index event
Medical therapy 22 (4) 4 (5) 0.98
CABG 6 (1) 0 0.72
PCI 489 (95) 75 (95) 0.89
PCI with stent 463 (90) 72 (91) 0.82
PCI with DES 406 (79) 66 (84) 0.38
Antithrombotic therapy up to 1-year
Aspirin 517 (100) 79 (100) -
Clopidogrel 145 (28) 39 (49) <0.001
Ticagrelor 265 (51) 28 (35) <0.001
Prasugrel 107 (21) 12 (16) 0.32
Triple therapy - -
TIMI risk score 2 (1;3) 3 (2;4) 0.34
PRECISE-DAPT risk score 14 (6;26) 18 (6–29) 0.13
Any bleeding up to one year 87 (17) 5 (6) 0.025
Thrombotic CV event up to one year 23 (4) 9 (11) 0.022
Number of drugs at one year follow-up 5 (4;6) 5 (4;6) 0.14
Values are expressed as median (interquartile range) or n. (%).
BMI = Body mass index; CABG = Coronary artery bypass graft; CV = Cardiovascular; DAPT = Dual antiplatelet therapy; DES = drug-eluting stent;
LVEF = Left ventricular ejection fraction; NSTE-ACS = Non ST-segment elevation acute coronary syndrome; MI = Myocardial infarction;
PCI = Percutaneous coronary intervention; STEMI = ST-segment elevation myocardial infarction; TIA = Transient ischemic attack.
*Defined as Haemoglobin <12.5 g/dL if male, <11.5 g/dL if female.
https://doi.org/10.1371/journal.pone.0186961.t001
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Discussion
In this prospective, real-world registry we have investigated clinical variables leading to pro-
longation of DAPT beyond one year from ACS. We found that DAPT was prolonged in 13%
of patients and independent predictors of prolongation were recurrent ischemic events, the
absence of anemia or bleeding during follow-up and concomitant renal failure or peripheral
artery disease. Instead, we observed no influence of lower age, diabetes mellitus or DES
implantation on DAPT continuation.
Fig 1. Logistic regression analysis for independent predictors of DAPT prolongation beyond one year after ACS. DAPT = Dual antiplatelet
therapy; Cr Cl = Creatinine clearance; DES = Drug-eluting stent; MACE = Major adverse cardiovascular events; PAD = Peripheral artery disease;
PCI = Percutaneous coronary intervention; STEMI = ST-segment elevation myocardial infarction; TIA = Transient ischemic attack.
https://doi.org/10.1371/journal.pone.0186961.g001
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Among patients with MI, observational data and post-hoc analyses of randomized trials
indicated a relevant residual cardiovascular risk over the long-term in those receiving aspirin
therapy alone [4–7] and suggested a clustering of adverse ischemic events in the first months
after DAPT discontinuation.[13] Therefore, in the last years a mounting evidence on the clini-
cal benefit of DAPT prolongation beyond one year after ACS has been made available. In par-
ticular, the DAPT trial compared 30 versus 12 months of DAPT with clopidogrel or prasugrel
plus aspirin after coronary stenting;[9] in this study the reduction in MACE for continued
thienopyridine was greater in the subgroup with MI as index event, but at the cost of increased
bleeding.[14] The other randomized investigation on the topic is the PEGASUS trial (8), in
which patients with a history of MI 1–3 years prior were enrolled and prolonged use of ticagre-
lor at two different doses (60 mg and 90 mg twice daily), given on top of aspirin therapy, was
associated with significant decrease of MACE versus placebo. Both ticagrelor arms showed
higher incidence of major bleeding complications, but no increase in fatal or intracranial
bleeding. Given its more favorable benefit/risk ratio, 60 mg twice daily has been considered
the dose of choice of ticagrelor for DAPT prolongation after an acute coronary event and rep-
resents the dose licensed in the Unites States and in various European countries. Of note, a
recent meta-analysis showed a 26% and 16% risk reduction of MACE and cardiovascular mor-
tality, respectively, with DAPT continuation at the price of>2-fold higher risk of non-fatal
major bleeding, especially when the newer, more potent P2Y12 antagonists were used.[15]
Thus, a careful evaluation of both bleeding and ischemic risk is mandatory in patients on
DAPT completing 1-year follow-up after ACS, when DAPT may be prolonged if the estimated
risk of ischemic events on aspirin alone overcomes the expected DAPT-related bleeding
propensity.
In the START ANTIPLATELET registry 13% of patients continued DAPT beyond one
year; powerful predictors of DAPT continuation were the absence of anemia or bleeding
events during 1-year follow-up (OR 2.6 and 3.2, respectively). Thus, in a real-world setting the
Fig 2. Median (interquartile range) score values in patients with and without DAPT prolongation. The atherothrombotic score derived from
the TRA 2˚P population indicates the risk of major adverse cardiac events, the PRECISE-DAPT score the risk of bleeding. DAPT = Dual antiplatelet
therapy.
https://doi.org/10.1371/journal.pone.0186961.g002
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concern of haemorrhagic complications related to a more aggressive antiplatelet treatment is
predominant for choosing the optimal antithrombotic strategy at one year after ACS; accord-
ingly, the perception of a low bleeding risk, characterized by the absence of anemia and no his-
tory of bleeding, identifies patients considered suitable for DAPT continuation. Notably,
anemia and history of bleeding have been included in several scores stratifying the bleeding
risk in patients receiving antithrombotic therapies.[12,16] However, in our study the clinical
perception of a low bleeding risk, resulting in DAPT continuation beyond one year, did not
translate into a lower bleeding risk profile as assessed by the PRECISE-DAPT score. Further-
more, patients with prior stroke or TIA are known to be at higher risk of bleeding complica-
tions during antithrombotic therapies; we observed a lower rate of DAPT continuation in
patients with prior stroke/TIA (9% vs 14%), not statistically significant due to the low number
of patients.
In our study markers of higher cardiovascular risk leading to DAPT prolongation were con-
comitant peripheral artery disease and chronic renal failure. Previous data showed that the
association of coronary and peripheral artery disease identifies patients with poorer cardiovas-
cular outcome,[17] and in the PEGASUS trial patients with concomitant peripheral artery dis-
ease achieved a larger net clinical benefit from use of ticagrelor.[18] In patients with coronary
disease the presence of chronic renal failure increases the risk of ischemic events; of note, use
of ticagrelor beyond one year was associated with greater absolute reduction of MACE in the
subgroup with renal failure.[19] Although renal failure is certainly also a predictor of elevated
bleeding risk, our real-world data indicate that in this setting of patients the concern of high
risk of ischemic events if DAPT is not prolonged outweighs the concern of DAPT-related
bleeding.
Older age (>75 years) has been demonstrated to significantly enhance the risk of bleeding
related to antiplatelet therapies with the newer, more potent agents, in particular prasugrel or
vorapaxar.[20–22] In START ANTIPLATELET, where, if considered indicated, DAPT pro-
longation was performed with clopidogrel as P2Y12 inhibitor, older age was not a deterrent
for stopping DAPT at one year. Of note, diabetes mellitus was not a predictor of DAPT contin-
uation. It is well known that diabetic patients have a higher prevalence of impaired response to
clopidogrel [23,24] and subgroup analysis from the CURE trial had suggested a lower ischemic
protection with aspirin plus clopidogrel vs aspirin alone in diabetic versus non-diabetic
patients with ACS;[25,26] of note, in the DAPT study the clinical benefit of the association
aspirin plus P2Y12 inhibitor was attenuated in patients with diabetes compared to those with-
out.[27] All those observations may contribute to explain our results on the lack of relationship
between presence of diabetes and DAPT prolongation. Moreover, we observed that DAPT
continuation was irrespective of the therapeutic strategy for the index event, i.e. it was per-
formed in patients treated with either medical therapy or PCI. This is consistent with findings
of the PLATO trial,[28] indicating an elevated risk of adverse events in patients unsuitable for
coronary revascularization after ACS; of note, the DAPT study showed that long-term DAPT,
beyond the reduction of events related to the culprit coronary vessel (i.e. stent thrombosis or
target vessel revascularization), prevented progression and destabilization of athero-throm-
botic processes in the entire coronary tree.[14] Finally, in the START ANTIPLATELET regis-
try there was not a higher prevalence of DAPT prolongation in patients receiving DES versus
bare metal stents (14% vs 11%); this is consistent with recent data showing that the risk of stent
thrombosis with the newer-generation DES is very low, whereas the risk of such complication
after bare metal stent implantation is not negligible.[29]
At the time of the START ANTIPLATELET registry ticagrelor 60 mg was not licensed in
Italy for long-term use after MI; when this formulation of ticagrelor will become available for
clinical use, other features of high bleeding risk (i.e. older age) are likely to become important
Predictors of DAPT prolongation after ACS
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for the decision on DAPT prolongation beyond one year with this drug. Moreover, in the
PEGASUS trial diabetic patients obtained a greater net clinical benefit from ticagrelor admin-
istration, [30] and it is possible that, unlike so far done, the presence of diabetes will become in
the near future an incentive for DAPT continuation beyond one year after MI. Of note, we
found that patients with DAPT prolongation had a significantly higher use of clopidogrel,
instead of the newer, more potent P2Y12 inhibitors, during 1-year follow-up; therefore, in the
real-world setting of our registry, a switching at one year from ticagrelor or prasugrel to clopi-
dogrel was not frequently performed, although patients receiving these more potent agents
after an ACS are usually at higher risk of ischemic events.
Risk scores, such as the score derived from the TRA 2˚P population and the PRECISE--
DAPT score (for ischemic and bleeding events, respectively), have been recently proposed as
useful tools to predict the risk of future adverse events and guide physicians in the selection of
patients who may derive a net benefit from prolonged DAPT.[11,12] However, our registry,
started before the diffusion of those scores, did not show any difference in either ischemic or
bleeding scores between patients who discontinued or prolonged DAPT at one year. It is possi-
ble that in the future a larger use of these scores in routine practice will implement the deci-
sion-making process regarding optimal DAPT duration after ACS.
We recognize limitations in our study. First, the study size is a relevant statistical limitation.
Moreover, bias in the patients’ selection and residual confounding cannot be excluded; finally,
we were not able to evaluate the predictive role for DAPT prolongation of various angio-
graphic and procedural variables (i.e. multivessel disease, multivessel intervention, degree of
coronary calcification, number of stents), because those variables were not collected.
In conclusion, START ANTIPLATELET provides a real-world snapshot about the decision
of prolonging DAPT beyond one year after ACS in a European country and describe clinical
factors influencing the choice of this strategy; moreover, it illustrates the relative contribution
of low bleeding risk versus high ischemic risk features for DAPT continuation. According to
our data, a low bleeding risk seems to weight more than a high ischemic risk in the current
decision for DAPT prolongation. It will be intriguing to evaluate how the predictors of DAPT
continuation will change after the introduction of 60 mg ticagrelor for long-term prevention
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